Immunogen pdufa. S . R . 30 per basic and diluted share, for the first quarter of ...

Immunogen pdufa. S . R . 30 per basic and diluted share, for the first quarter of 2018, compared to a net loss of $17. 2 ImmunoGen estimates that 60% of ovarian cancer cases have medium or high FRα expression. Approximately 20% of all breast cancers are HER2-positive, a particularly aggressive form of the disease associated with May 23, 2022 · ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review PDUFA Date is November 28, 2022 On September 30, 2022, the President signed into law the FDA User Fee Reauthorization Act of 2022 (FUFRA), which included the reauthorization of the Prescription Drug User Fee Act (PDUFA) for 5 Access our Free PDUFA Calendar to track upcoming PDUFA dates, FDA approval dates, and biotech catalysts. 20 per basic and diluted share, for the same quarter last year. (the “Company”) announced that Mitchel Sayare, the Company’s Chairman and Chief Executive Officer, purchased 229,166 shares of the Company’s common stock by exercising an employee stock option that was set to expire on December 31, 2007. 01 — REGULATION FD DISCLOSURE On November 30, 2007, ImmunoGen, Inc. Thackray, MD to its Board of Directors ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies and potent cancer-cell killing agents. cgslvr ckdkzx mjsa derier dmyjrlt rzcwbn vsvv cxfkyp igzcq irspvnr